A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is a three arm study to determine the maximum tolerated dose (MTD) of ABT-263 when
administered in combination with erlotinib (Arm A), to determine the maximum tolerated dose
(MTD) of ABT-263 when administered in combination with irinotecan (Arm B), and to evaluate
safety of ABT-263 monotherapy (Arm C).